title: Pituitary-directed medical therapy in Cushing's disease.
abstract: Transsphenoidal surgery remains the first line therapy in Cushing's disease, but a large number of patients will not be cured or disease will recur over time. Repeat pituitary surgery, bilateral adrenalectomy, and radiation have limitations with respect to efficacy and/or side effects. Therefore, there is a clear need for an effective medical treatment. The studies reviewed here suggest a role for pituitary-directed therapies, applying multireceptor ligand somatostatin analogs like pasireotide or second-generation dopamine agonists. Retinoic acid has been also studied in a small prospective study. These compounds target ACTH-secretion at the pituitary level and possibly inhibit corticotrope proliferation. Specific side effects of these compounds need to be considered, especially when used as long-term therapy. These novel approaches could provide options for treatment of patients in whom surgery has failed or is not possible, and while awaiting effects of radiation therapy. Preoperative use to decrease cortisol excess, potentially reducing perioperative complications, needs to be further studied.
authors: ENDOC Center for Endocrine Tumors, Altonaer Str. 59, 20357, Hamburg, Germany, stephan.petersenn@endoc-med.de.
authors: Stephan
authors: S
authors: Petersenn
authors: Maria
authors: M
authors: Fleseriu
mesh_terms: D049913:ACTH-Secreting Pituitary Adenoma / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000236:Adenoma / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D047748:Pituitary ACTH Hypersecretion / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D013004:Somatostatin; D014212:Tretinoin
references: Pituitary. 2015 Jun;18(3):359-65
references: 24952218
references: Pituitary. 2014 Dec;17(6):519-29
references: 24287689
references: Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):330-4
references: 23807605
references: J Clin Endocrinol Metab. 2009 Jan;94(1):223-30
references: 18957500
references: Eur J Endocrinol. 2005 Apr;152(4):645-54
references: 15817922
references: Rev Endocr Metab Disord. 2009 Jun;10(2):91-102
references: 18642088
references: Endocr Pract. 2013 Jul-Aug;19(4):e92-6
references: 23512383
references: FEBS Lett. 1994 Feb 14;339(1-2):73-5
references: 7508871
references: Pituitary. 2014 Aug;17(4):320-6
references: 23943009
references: Clin Endocrinol (Oxf). 1986 Dec;25(6):661-7
references: 3115630
references: Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E278-87
references: 15769796
references: Neuroendocrinology. 2010;92 Suppl 1:17-22
references: 20829613
references: Pituitary. 2012 Dec;15 Suppl 1:33-6
references: 22038028
references: Eur J Endocrinol. 2010 Nov;163(5):709-16
references: 20702648
references: Neuroendocrinology. 2004;80 Suppl 1:47-50
references: 15477717
references: Best Pract Res Clin Endocrinol Metab. 2009 Dec;23 Suppl 1:S15-22
references: 20129190
references: N Engl J Med. 2007 Jan 4;356(1):39-46
references: 17202454
references: Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17
references: 24533697
references: J Clin Endocrinol Metab. 2006 Nov;91(11):4482-8
references: 16940446
references: J Clin Endocrinol Metab. 2004 May;89(5):2452-62
references: 15126577
references: N Engl J Med. 2007 Jan 4;356(1):29-38
references: 17202453
references: Clin Endocrinol (Oxf). 2014 Feb;80(2):261-9
references: 23746264
references: J Neurooncol. 2013 Aug;114(1):1-11
references: 23673515
references: Pituitary. 2012 Sep;15(3):330-41
references: 22674211
references: J Clin Endocrinol Metab. 2012 Oct;97(10):3577-83
references: 22851491
references: Clin Endocrinol (Oxf). 2009 Aug;71(2):305-7
references: 19067723
references: J Clin Invest. 2001 Oct;108(8):1123-31
references: 11602619
references: Eur J Endocrinol. 2014 Jul;171(1):89-98
references: 24760537
references: J Clin Endocrinol Metab. 2005 May;90(5):3077-83
references: 15705919
references: N Engl J Med. 2012 Mar 8;366(10):914-24
references: 22397653
references: J Clin Endocrinol Metab. 2013 May;98(5):1803-7
references: 23539733
references: Endocrine. 2001 Apr;14(3):329-36
references: 11444429
references: Endocr Rev. 2005 Oct;26(6):775-99
references: 15827110
references: Clin Endocrinol (Oxf). 1981 Nov;15(5):479-84
references: 6276051
references: Clin Endocrinol (Oxf). 1988 Feb;28(2):215-23
references: 2844447
references: Eur J Endocrinol. 2014 Feb 01;170(2):181-91
references: 24165019
references: Endocrinology. 2006 Sep;147(9):4438-44
references: 16740975
references: Endocr Rev. 1993 Aug;14 (4):443-58
references: 7693447
references: J Clin Endocrinol Metab. 2009 Jan;94(1):115-22
references: 18957506
references: Eur J Endocrinol. 2002 May;146(5):707-16
references: 11980628
references: N Engl J Med. 2012 May 31;366(22):2134; author reply 2134-5
references: 22646647
references: Pituitary. 2015 Feb;18(1):60-7
references: 24482099
references: Pituitary. 2012 Dec;15(4):608-13
references: 22918543
references: Obstet Gynecol. 2013 Aug;122(2 Pt 2):485-7
references: 23884269
references: BMJ Case Rep. 2012 Jul 03;2012:null
references: 22761217
references: J Clin Endocrinol Metab. 2009 Nov;94(11):4342-50
references: 19820006
references: J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62
references: 18413427
references: Nat Clin Pract Endocrinol Metab. 2008 Jun;4(6):344-50
references: 18446140
references: Eur J Endocrinol. 2005 Jun;152(6):887-94
references: 15941929
references: Eur J Endocrinol. 2012 Apr;166(4):613-8
references: 22214924